Endometriosis is a serious gynecological disease with a global incidence of 10. This disease will have a serious impact on women’s daily lives, including severe abdominal pain, massive organ bleeding, sexual behavior difficulties, infertility,even high-risk cancer progression. We discover that the karyotype variation of ribosomes is closely related to the deterioration of endometriosis. We collaborate with Hospital on human clinical trials to develop in vitro diagnostic devices that can screen early stage of Endometriosis. It can avoid unnecessary riskscosts of discovering diseases.

Current diagnostic methods for endometriosis include palpation, ultrasoundCA-125. Traditional medical testing of Endometriosis requires a lot of timeenergy to go through multiple tests.  These reasons not only lead to a serious stage of disease when diagnosed but also cause greater medical riskscosts. However, the in vitro diagnostic reagents we developed has the advantages of fastprecision. At the same time, the characteristic of using at home is very convenient. So, we can do the rapid disease diagnostic test for large number of people to save their healthmoney.

US is the first to use genetic testing into Direct-to-Consumer Genetic Testing(DTC) market. DTC model allows US FDA approved testing services to be provided directly by suppliers to consumers through the Internet. Especially after covid-19, telemedicine has become a trend. According to the US CDC, more than 600000 women perform hysterectomy(cost 20000 USD)every year, 40 of them are patients with endometriosis. Therefore, if the disease is detected early through our products, there is a very great chance to cure it by drugs alone,the treatment cost will be reduced to 2000 US dollars.

天使投資人、策略合作夥伴